Bortezomib generally refers to bortezomib for injection, and a course of treatment usually involves 2-3 injections. The medication can only be used intravenously and is usually given twice a week for a three-week course of treatment, with each course of treatment usually requiring 2-3 injections. The drug has the properties of a white or off-white mass, powder, and is usually used to treat multiple myeloma in combination with melphalan as well as hyaluronic acid in patients with untreated multiple myeloma who are not candidates for high-dose chemotherapy or bone marrow transplantation. However, it should be noted that the drug is contraindicated in patients who are allergic to bortezomib, boron or mannitol. It should be noted that when using drugs for treatment, professional examination should be carried out to clarify the contraindications and precautions for the use of drugs, and standardized application under the guidance of a professional doctor to avoid blind use of drugs, causing adverse reactions.